Literature DB >> 25425208

A simple and low-cost platform technology for producing pexiganan antimicrobial peptide in E. coli.

Chun-Xia Zhao1, Mirjana Dimitrijev Dwyer, Alice Lei Yu, Yang Wu, Sheng Fang, Anton P J Middelberg.   

Abstract

Antimicrobial peptides, as a new class of antibiotics, have generated tremendous interest as potential alternatives to classical antibiotics. However, the large-scale production of antimicrobial peptides remains a significant challenge. This paper reports a simple and low-cost chromatography-free platform technology for producing antimicrobial peptides in Escherichia coli (E. coli). A fusion protein comprising a variant of the helical biosurfactant protein DAMP4 and the known antimicrobial peptide pexiganan is designed by joining the two polypeptides, at the DNA level, via an acid-sensitive cleavage site. The resulting DAMP4(var)-pexiganan fusion protein expresses at high level and solubility in recombinant E. coli, and a simple heat-purification method was applied to disrupt cells and deliver high-purity DAMP4(var)-pexiganan protein. Simple acid cleavage successfully separated the DAMP4 variant protein and the antimicrobial peptide. Antimicrobial activity tests confirmed that the bio-produced antimicrobial peptide has the same antimicrobial activity as the equivalent product made by conventional chemical peptide synthesis. This simple and low-cost platform technology can be easily adapted to produce other valuable peptide products, and opens a new manufacturing approach for producing antimicrobial peptides at large scale using the tools and approaches of biochemical engineering.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  antimicrobial peptide; chromatography-free; expression; precipitation; purification; recombinant

Mesh:

Substances:

Year:  2015        PMID: 25425208     DOI: 10.1002/bit.25505

Source DB:  PubMed          Journal:  Biotechnol Bioeng        ISSN: 0006-3592            Impact factor:   4.530


  6 in total

Review 1.  Peptide-Based Inhibitors for SARS-CoV-2 and SARS-CoV.

Authors:  Disha Panchal; Jeena Kataria; Kamiya Patel; Kaytlyn Crowe; Varun Pai; Abdul-Rahman Azizogli; Neil Kadian; Sreya Sanyal; Abhishek Roy; Joseph Dodd-O; Amanda M Acevedo-Jake; Vivek A Kumar
Journal:  Adv Ther (Weinh)       Date:  2021-08-06

2.  Cost-effective downstream processing of recombinantly produced pexiganan peptide and its antimicrobial activity.

Authors:  Baode Sun; David Wibowo; Anton P J Middelberg; Chun-Xia Zhao
Journal:  AMB Express       Date:  2018-01-24       Impact factor: 3.298

3.  Structure-function-guided exploration of the antimicrobial peptide polybia-CP identifies activity determinants and generates synthetic therapeutic candidates.

Authors:  Marcelo D T Torres; Cibele N Pedron; Yasutomi Higashikuni; Robin M Kramer; Marlon H Cardoso; Karen G N Oshiro; Octávio L Franco; Pedro I Silva Junior; Fernanda D Silva; Vani X Oliveira Junior; Timothy K Lu; Cesar de la Fuente-Nunez
Journal:  Commun Biol       Date:  2018-12-07

4.  Evaluation of baiting fipronil-loaded silica nanocapsules against termite colonies in fields.

Authors:  Brenton C Peters; David Wibowo; Guang-Ze Yang; Yue Hui; Anton P J Middelberg; Chun-Xia Zhao
Journal:  Heliyon       Date:  2019-08-10

Review 5.  Antimicrobial peptides: new hope in the war against multidrug resistance.

Authors:  James Mwangi; Xue Hao; Ren Lai; Zhi-Ye Zhang
Journal:  Zool Res       Date:  2019-11-18

6.  Rational Design of a Carrier Protein for the Production of Recombinant Toxic Peptides in Escherichia coli.

Authors:  Katia Pane; Lorenzo Durante; Elio Pizzo; Mario Varcamonti; Anna Zanfardino; Valeria Sgambati; Antimo Di Maro; Andrea Carpentieri; Viviana Izzo; Alberto Di Donato; Valeria Cafaro; Eugenio Notomista
Journal:  PLoS One       Date:  2016-01-25       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.